⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30790700 | 1.00 | — | — | |
| SCHEMBL16088307 | 1.00 | — | — | |
| SCHEMBL30790692 | 0.83 | MAPK1 (0.34) | — | |
| SCHEMBL16040435 | 0.83 | MAPK1 (0.34) | — | |
| SCHEMBL16091552 | 0.83 | MAPK1 (0.34) | — | |
| SCHEMBL16040024 | 0.83 | SYK (0.43) | — | |
| SCHEMBL29578990 | 0.83 | SYK (0.43) | — | |
| SCHEMBL30790693 | 0.83 | SYK (0.43) | — | |
| SCHEMBL16038633 | 0.83 | SYK (0.43) | — | |
| SCHEMBL16088308 | 0.80 | ADRA1D (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12251387-B2 | Substituted quinoxalines and benzo[c][1,2,5]oxadiazoles as DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-03-18 | — | — | US | disclosed |
| EP-3740479-B1 | DNA-PK INHIBITORS | VERTEX PHARMA (US) | 2024-11-20 | — | — | EP | disclosed |
| US-12121524-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-10-22 | — | — | US | disclosed |
| US-20230277547-A1 | SUBSTITUTED QUINOXALINE DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-09-07 | — | — | US | disclosed |
| EP-3985003-B1 | DNA-PK INHIBITORS | VERTEX PHARMA (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-3985003-B1 | DNA-PK INHIBITORS | VERTEX PHARMA (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-3985003-A1 | DNA-PK INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2022-04-20 | — | — | EP | disclosed |
| US-20210236505-A1 | SUBSTITUTED QUINOXALINE DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-08-05 | — | — | US | disclosed |
| US-10973830-B2 | Substituted quinoxaline DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-04-13 | — | — | US | disclosed |
| US-20210060028-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2021-03-04 | — | — | US | disclosed |
| US-20190290654-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-09-26 | — | — | US | disclosed |
| EP-3527563-A1 | DNA-PK INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2019-08-21 | — | — | EP | disclosed |
| EP-2970218-B1 | DNA-PK INHIBITORS | VERTEX PHARMA (US) | 2018-11-28 | — | — | EP | disclosed |
| US-20180311254-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-11-01 | — | — | US | disclosed |
| US-9987284-B2 | Substituted benzooxadiazole DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-06-05 | — | — | US | disclosed |
| US-20160340341-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-11-24 | — | — | US | disclosed |
| US-9340557-B2 | Substituted quinoxaline DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-05-17 | — | — | US | disclosed |
| EP-2970218-A1 | DNA-PK INHIBITORS | Vertex Pharmaceuticals Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014159690-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20140275024-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-18 | — | — | US | disclosed |